How to improve our ability to predict adverse events in major surgery of SLE patients?

Autoimmunity Reviews

Volumn 10, Issue 9, 2011, Pages 525-526

  Bertero, Tiziana ^a   Parisi, Francesco ^b   De Rosa, Giovanni ^c   Sciascia, Savino ^a  

^a UNIVERSITY OF TURIN   (Italy)

^b UO Cardiochirurgia   (Italy)

^c UO Anatomia Patologica   (Italy)

Author keywords

Disease activity; Organ damage; SLE

Indexed keywords

ACETYLSALICYLIC ACID; ANTIHYPERTENSIVE AGENT; AZATHIOPRINE; CYCLOPHOSPHAMIDE; CYCLOSPORIN; MYCOPHENOLIC ACID; STEROID;

ANTIPHOSPHOLIPID SYNDROME; AORTA ANEURYSM; AORTA VALVE REGURGITATION; AORTA VALVE REPLACEMENT; ARTICLE; ASCENDING AORTA SURGERY; AUTOIMMUNE HEMOLYTIC ANEMIA; CANDIDEMIA; CASE REPORT; CHILD; DISEASE COURSE; FEMALE; HEART MUSCLE ISCHEMIA; HUMAN; INTESTINE ISCHEMIA; KIDNEY FAILURE; LUNG INFECTION; MORTALITY; PANCREATITIS; SCHOOL CHILD; SPINAL HEMATOMA; SURGICAL PATIENT; SYSTEMIC LUPUS ERYTHEMATOSUS; THROMBOCYTOPENIA;

ADULT; AORTA; AORTIC VALVE; AORTIC VALVE INSUFFICIENCY; FATAL OUTCOME; FEMALE; HUMANS; LUPUS ERYTHEMATOSUS, SYSTEMIC; POSTOPERATIVE COMPLICATIONS; PROGNOSIS; PROSTHESES AND IMPLANTS; TRANSPLANTATION, AUTOLOGOUS; TREATMENT FAILURE;

EID: 79957914348     PISSN: 15689972     EISSN: 18730183     Source Type: Journal    
DOI: 10.1016/j.autrev.2011.04.002     Document Type: Article

References (13)

1. Soltész P., Kerekes G., Dér H., et al. Comparative assessment of vascular function in autoimmune rheumatic diseases: considerations of prevention and treatment. Autoimmun Rev Jan 3 2011, [Epub ahead of print].
2. Nossent J., Kiss E., Rozman B., et al. Disease activity and damage accrual during the early disease course in a multinational inception cohort of patients with systemic lupus erythematosus. Lupus 2010, 19:949-956.
3. Mosca M., Tani C., Aringer M., et al. European League Against Rheumatism recommendations for monitoring patients with systemic lupus erythematosus in clinical practice and in observational studies. Ann Rheum Dis 2010, 69:1269-1274.
4. Sarzi-Puttini P., Atzeni F., Gerli R., et al. Cardiac involvement in systemic rheumatic diseases: an update. Autoimmun Rev 2010, 9:849-852.
5. Ruiz-Irastorza G., Ramos-Casals M., Brito-Zeron P., et al. Clinical efficacy and side effects of antimalarials in systemic lupus erythematosus: a systematic review. Ann Rheum Dis 2010, 69:20-28.
6. Himmelfarb J., Ikizler T.A. Hemodialysis. N Engl J Med 2010, 363:1833-1845.
7. Sitia S., Tomasoni L., Atzeni F., et al. From endothelial dysfunction to atherosclerosis. Autoimmun Rev 2010, 9:830-834.
8. Sule S., Fivush B., Neu A., et al. Increased risk of death in pediatric and adult patients with ESRD secondary to lupus. Pediatr Nephrol 2010, 49:2381-2390.
9. Yildiz M. Arterial distensibility in chronic inflammatory rheumatic disorders. Open Cardiovasc Med J 2010, 4:83-88.
10. Zardi E.M., Afeltra A. Endothelial dysfunction and vascular stiffness in systemic lupus erythematosus: are they early markers of subclinical atherosclerosis?. Autoimmun Rev 2010, 9:684-686.
11. Costedoat-Chalumeau N., Leroux G., Piette J.C., et al. Why all systemic lupus erythematosus patients should be given hydroxychloroquine treatment ?. Joint Bone Spine 2010, 77:4-5.
12. Koniari I., Siminelakis S., Baikoussis N., et al. Antiphospholipid syndrome; its implication incardiovascular diseases: a review. J Cardiothoracic Surgery 2010, 5:101.
13. Gladman D.D., Urowitz M.B., Goldsmith C.H., et al. Reliability of the Systemic Lupus International collaborating Clinics/American College of Rheumathology Damage Index in patients with Systemic Lupus Erythematosus. Arthritis Rheum 1997, 40:809-813.